TScan Therapeutics IncNASDAQ:TCRX
- LAST PRICE4.5350
- TODAY'S CHANGE (%)0.2750 (6.4554%)
- Bid / Lots4.5000/ 1
- Ask / Lots4.8100/ 3
- Open / Previous Close4.3600 / 4.2600
- Day Range
- 52 Week Range
- Volume192,247
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCRX |
|---|---|---|
| 09:32 ET | 4409 | 4.3 |
| 09:33 ET | 100 | 4.34 |
| 09:35 ET | 100 | 4.46 |
| 09:37 ET | 100 | 4.45 |
| 09:39 ET | 400 | 4.4499 |
| 09:42 ET | 4100 | 4.42 |
| 09:44 ET | 200 | 4.48 |
| 09:46 ET | 100 | 4.48 |
| 09:48 ET | 400 | 4.48 |
| 09:50 ET | 100 | 4.48 |
| 09:51 ET | 300 | 4.445 |
| 09:53 ET | 1433 | 4.45 |
| 09:55 ET | 1800 | 4.46 |
| 09:57 ET | 3325 | 4.47 |
| 10:00 ET | 1700 | 4.445 |
| 10:02 ET | 4647 | 4.48 |
| 10:04 ET | 2200 | 4.48 |
| 10:06 ET | 200 | 4.48 |
| 10:08 ET | 200 | 4.48 |
| 10:11 ET | 10500 | 4.48 |
| 10:13 ET | 100 | 4.48 |
| 10:15 ET | 100 | 4.47 |
| 10:18 ET | 332 | 4.515 |
| 10:27 ET | 450 | 4.59 |
| 10:29 ET | 200 | 4.63 |
| 10:40 ET | 100 | 4.65 |
| 10:42 ET | 200 | 4.6699 |
| 10:47 ET | 200 | 4.675 |
| 10:49 ET | 3200 | 4.71 |
| 10:51 ET | 3930 | 4.705 |
| 10:54 ET | 100 | 4.705 |
| 10:56 ET | 300 | 4.7 |
| 10:58 ET | 3998 | 4.7 |
| 11:00 ET | 500 | 4.695 |
| 11:02 ET | 4400 | 4.68 |
| 11:03 ET | 500 | 4.68 |
| 11:05 ET | 100 | 4.665 |
| 11:07 ET | 250 | 4.65 |
| 11:09 ET | 100 | 4.62 |
| 11:12 ET | 637 | 4.595 |
| 11:23 ET | 847 | 4.575 |
| 11:25 ET | 161 | 4.575 |
| 11:27 ET | 200 | 4.575 |
| 11:30 ET | 100 | 4.6 |
| 11:32 ET | 200 | 4.575 |
| 11:34 ET | 655 | 4.595 |
| 11:39 ET | 695 | 4.57 |
| 11:45 ET | 773 | 4.6 |
| 11:48 ET | 589 | 4.575 |
| 11:52 ET | 800 | 4.56 |
| 11:57 ET | 200 | 4.5461 |
| 12:03 ET | 200 | 4.55 |
| 12:06 ET | 802 | 4.59 |
| 12:14 ET | 200 | 4.57 |
| 12:19 ET | 279 | 4.55 |
| 12:21 ET | 537 | 4.59 |
| 12:24 ET | 407 | 4.55 |
| 12:26 ET | 1300 | 4.525 |
| 12:28 ET | 2000 | 4.525 |
| 12:32 ET | 100 | 4.525 |
| 12:37 ET | 2003 | 4.54 |
| 12:42 ET | 4391 | 4.5799 |
| 12:44 ET | 3431 | 4.585 |
| 12:46 ET | 346 | 4.58 |
| 12:48 ET | 100 | 4.565 |
| 12:51 ET | 100 | 4.54 |
| 01:02 ET | 117 | 4.5661 |
| 01:04 ET | 503 | 4.58 |
| 01:08 ET | 100 | 4.585 |
| 01:09 ET | 400 | 4.585 |
| 01:13 ET | 500 | 4.6 |
| 01:15 ET | 500 | 4.6 |
| 01:18 ET | 300 | 4.6 |
| 01:20 ET | 684 | 4.57 |
| 01:22 ET | 500 | 4.5871 |
| 01:24 ET | 100 | 4.545 |
| 01:29 ET | 556 | 4.51 |
| 01:31 ET | 215 | 4.5116 |
| 01:33 ET | 200 | 4.53 |
| 01:36 ET | 453 | 4.54 |
| 01:38 ET | 314 | 4.55 |
| 01:47 ET | 100 | 4.53 |
| 01:51 ET | 400 | 4.525 |
| 01:56 ET | 400 | 4.51 |
| 02:00 ET | 100 | 4.51 |
| 02:02 ET | 200 | 4.51 |
| 02:03 ET | 109 | 4.52 |
| 02:09 ET | 532 | 4.54 |
| 02:14 ET | 400 | 4.55 |
| 02:16 ET | 100 | 4.55 |
| 02:18 ET | 200 | 4.55 |
| 02:21 ET | 500 | 4.54 |
| 02:23 ET | 100 | 4.545 |
| 02:32 ET | 100 | 4.54 |
| 02:41 ET | 200 | 4.54 |
| 02:50 ET | 212 | 4.55 |
| 02:52 ET | 100 | 4.545 |
| 02:56 ET | 100 | 4.545 |
| 02:57 ET | 300 | 4.545 |
| 03:01 ET | 200 | 4.545 |
| 03:03 ET | 100 | 4.545 |
| 03:06 ET | 500 | 4.515 |
| 03:10 ET | 188 | 4.515 |
| 03:15 ET | 200 | 4.515 |
| 03:19 ET | 100 | 4.515 |
| 03:21 ET | 4813 | 4.5 |
| 03:24 ET | 600 | 4.49 |
| 03:26 ET | 500 | 4.52 |
| 03:28 ET | 100 | 4.4897 |
| 03:30 ET | 429 | 4.52 |
| 03:32 ET | 400 | 4.53 |
| 03:33 ET | 472 | 4.525 |
| 03:42 ET | 200 | 4.525 |
| 03:46 ET | 2426 | 4.55 |
| 03:48 ET | 100 | 4.55 |
| 03:50 ET | 328 | 4.525 |
| 03:51 ET | 380 | 4.525 |
| 03:53 ET | 400 | 4.51 |
| 03:55 ET | 1200 | 4.52 |
| 03:57 ET | 1060 | 4.51 |
| 04:00 ET | 34757 | 4.535 |
Nov 15, 2024
DJ TScan Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 6:44AM ET on Friday Nov 15, 2024 by Dow Jones
6:44AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 12, 2024
DJ TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham, from 12:38PM ET on Tuesday Nov 12, 2024 by Dow Jones
12:38PM ET on Tuesday Nov 12, 2024 by Dow JonesTScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
DJ TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham, from 5:29AM ET on Wednesday Nov 06, 2024 by Dow Jones
5:29AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TScan Therapeutics Inc | 225.7M | -4.3x | --- |
Mediwound Ltd | 177.8M | -8.0x | --- |
C4 Therapeutics Inc | 300.0M | -2.6x | --- |
Fennec Pharmaceuticals Inc | 145.9M | -56.2x | --- |
Uniqure NV | 281.7M | -1.2x | --- |
Molecular Partners AG | 219.0M | -2.9x | --- |
Company Information
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Contact Information
- Headquarters
- 880 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 857-399-9500
- Fax
- 302-531-3150
Executives
- Independent Non-Executive Chairman of the Board
- Stephen Biggar
- Chief Executive Officer, Director
- Gavin Macbeath
- Principal Financial Officer, Principal Accounting Officer, Treasurer
- Jason Amello
- Chief Medical Officer
- Chrystal Louis
- Chief Legal and Strategy Officer and Secretary
- Zoran Zdraveski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $225.7M |
|---|---|
Revenue (TTM) | $9.4M |
Shares Outstanding | 53.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-1.05 |
Book Value | $3.15 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 24.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,276.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
